Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Galapagos Initiates Clinical Studies With GLPG0187, A Candidate Drug For Bone Metastasis
Galapagos NV (Euronext: GLPG) announced that it has initiated Phase I clinical development of its integrin receptor antagonist (IRA), GLPG0187. This is the second small molecule therapeutic from Galapagos" internal drug discovery program to enter the clinic in 2009. Candidate drug GLPG0187 could offer a promising new therapeutic approach for treating cancer patients. Initial development will focus on bone metastases from prostate and breast cancer.
generic viagra online
Researchers Examine The Psychological Impact Of Child Abuse
According to a new Mayo Clinic study, a history of child abuse significantly impacts the wide range of challenges facing depressed inpatients. Included are an increase in suicide attempts, prevalence of substance use disorder, and a higher incidence rate of personality disorder. Additionally, these victims also had an earlier onset of mental illness and an increase in psychiatric hospitalizations for psychiatric issues. The study was presented at the American Psychiatric Association 2009 Annual Meeting in San Francisco.
News of the day
The 'Other' Cruciate Ligament: Newer Treatments For PCL Tears
While major advances have been made in the understanding of posterior cruciate ligament (PCL) anatomy and reconstruction, a literature review published in the July 2009 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) finds that there must be continued advances in basic science research in order to determine the best course of treatment for those with PCL injuries.
Endocrinology

Bio Manufacturers Poised To Follow Senate Victory With House Win

"A veteran California lawmaker with ties to the biotechnology industry said she thinks her proposal to protect brand-name biologic makers has enough support to carry in the House Energy and Commerce Committee," Dow Jones Newswires/Wall Street Journal reports. The proposal, by Rep. Anna Eshoo, D-Calif., would protect brand-name biologic products from competition for 12 years. A similar proposal cleared the Senate health committee earlier this week. Opponents of the proposal include the White House, the Federal Trade Commission and consumer groups like the AARP, "the influential lobby for the elderly," which "said it was disappointed with the Senate committee"s vote and "has great difficulty supporting legislation that would delay the availability of safe, affordable generic biologic drugs and impede consumer access to these life-saving drugs."" Rep. Henry Waxman, D-Calif., chairman of the Energy and Commerce Committee, has proposed protecting trademark products for only five to seven years. "Any legislation will likely affect the bottom lines of biologic makers such as Amgen Inc., Johnson & Johnson and Genentech Inc., and the wallets of consumers," Dow Jones reports. The sweeping health reform plan released yesterday did not include language on biologics, but Eshoo plans to introduce an amendment this week (Favole, 7/14). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009